10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
The Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness, today announced the launch of Opus Genetics, a patient-focused gene therapy company efficiently developing therapies for orphan inherited retinal diseases, based in Raleigh, North Carolina, USA. 22 September 2021
US pharma giant Pfizer and German partner BioNTech have reached agreement with the US government to provide an additional 500 million doses of their COVID-19 vaccine – trade-named Comirnaty - at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them 22 September 2021
Announcing a second Asian out-licensing deal for its rare liver disease drug candidate, US biotech Mirum Pharmaceuticals has now granted exclusive rights to market maralixibat in Japan to Takeda Pharmaceutical. 22 September 2021
A combination of Phase III data and real-world evidence show the safety and efficacy of offering a booster shot of Johnson & Johnson’s coronavirus vaccine. 22 September 2021
Canada’s AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly (NYSE: LLY) have entered into a joint procurement agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. 22 September 2021
US biotech bluebird bio says it has completed the rolling submission of its Biologics License Application (BLA) to the US Food and Drug Administration for betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions, across all genotypes. 22 September 2021
Research undertaken at the University of Bristol, UK, paves the way for a novel artificial intelligence (AI)-driven platform for growing and treating virtual tumors. 22 September 2021
Pharma giant Novartis today announced that it has acquired fellow Switzerland-based Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. 22 September 2021
The US Food and Drug Administration has approved Cabometyx (cabozantinib) for the additional indication of the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. 21 September 2021
Privately-held US immune-oncology firm Vigeo Therapeutics today announced completion of the Phase I/II dose expansion studies evaluating its lead asset VT1021 in recurrent glioblastoma (rGBM) and pancreatic cancer. 21 September 2021
German family-owned drugmaker Boehringer Ingelheim says it has acquired Abexxa Biologics, a biopharmaceutical company taking a new approach in the fields of immuno-oncology (I-O) and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. 21 September 2021
US cancer specialist Verastem Oncology saw its shares briefly spike by as much as 29% Monday morning, after announcing a clinical collaboration agreement with biotech major Amgen to evaluate the combination of VS-6766, Verastem’s investigational dual RAF/MEK inhibitor, with Amgen’s KRAS G12C inhibitor Lumakras (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC). 21 September 2021
Research from industry analyst GlobalData finds an increasing rate of dealmaking in India in recent quarters, propelled by the coronavirus pandemic. 21 September 2021
Data from the Phase III IMpower010 trial testing Tecentriq (atezolizumab) after surgery and chemo in lung cancer show a 34% reduction in the risk of disease recurrence or death. 21 September 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024